Technical Analysis for ACHL - Achilles Therapeutics plc

Grade Last Price % Change Price Change
C 15.15 3.77% 0.55
ACHL closed up 3.77 percent on Friday, April 16, 2021, on 20 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical ACHL trend table...

Date Alert Name Type % Chg
Up 3 Days in a Row Strength 0.00%
New 52 Week Closing Low Bearish 16.81%
Hot IPO Pullback Bullish Swing Setup 16.81%
NR7 Range Contraction 16.81%
Inside Day Range Contraction 16.81%
Down 3 Days in a Row Weakness 16.81%
Down 4 Days in a Row Weakness 16.81%
Down 5 Days in a Row Weakness 16.81%
New 52 Week Closing Low Bearish 16.09%
Hot IPO Pullback Bullish Swing Setup 16.09%
Older End-of-Day Signals for ACHL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatments Cancer Immunotherapy Melanoma Antineoplastic Drugs Bladder Cancer Head And Neck Cancer Breakthrough Therapy Renal Cell Carcinoma Triple Negative Breast Cancer Orphan Drugs Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical

Is ACHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.9476
52 Week Low 12.6668
Average Volume 190,374
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 14.62
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.02
MACD Signal Line 0.00
MACD Histogram 0.0157
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.65
Resistance 3 (R3) 16.48 15.82 16.40
Resistance 2 (R2) 15.82 15.43 15.90 16.32
Resistance 1 (R1) 15.48 15.20 15.65 15.65 16.23
Pivot Point 14.82 14.82 14.90 14.90 14.82
Support 1 (S1) 14.48 14.43 14.65 14.65 14.07
Support 2 (S2) 13.82 14.20 13.90 13.98
Support 3 (S3) 13.48 13.82 13.90
Support 4 (S4) 13.65